Clinical Policy: Rucaparib (Rubraca)
Reference Number: CP.PHAR.350
Effective Date: 09.01.17
Last Review Date: 02.21
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Rucaparib (Rubraca®) is a poly (ADP-ribose) polymerase (PARP) inhibitor.

FDA Approved Indication(s)
Rubraca is indicated:

Ovarian cancer
- For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- For the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.

Prostate cancer
- For the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.

This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Rubraca is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Ovarian Cancer (must meet all):
      1. Diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer;
      2. Prescribed by or in consultation with an oncologist;
      3. Age ≥ 18 years;
      4. For Rubraca request, medical justification supports inability to use rucaparib, if available, (e.g., contraindications to excipients);
5. Prescribed as a single agent;
6. Member meets one of the following (a or b):*
   a. Completion of ≥ 2 platinum-based (e.g., carboplatin, cisplatin, oxaliplatin) chemotherapy regimens with complete or partial response;
   b. Documented deleterious germline and/or somatic BRCA mutation, and failure of ≥ 2 lines of chemotherapy (see Appendix B), unless all are contraindicated or clinically significant adverse effects are experienced;
*Prior authorization may be required
7. Member has not previously received a PARP inhibitor (e.g., Lynparza®, Talzenna®, Zejula®) (see Appendix D);
8. Request meets one of the following (a or b):*
   a. Dose does not exceed 1,200 mg (4 tablets) per day;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Medicaid/HIM – 6 months
Commercial – Length of Benefit

B. Prostate Cancer (must meet all):
1. Diagnosis of metastatic CRPC as evidenced by disease progression despite androgen deprivation therapy (ADT) (see Appendix D);
2. Prescribed by or in consultation with an oncologist or urologist;
3. Age ≥ 18 years;
4. Documented deleterious germline and/or somatic BRCA mutation;
5. For Rubraca request, medical justification supports inability to use rucaparib, if available, (e.g., contraindications to excipients);
6. Prescribed concurrently with systemic ADT (see Appendix D) or member has had a bilateral orchectomy;
7. Failure of both of the following, unless clinically significant adverse effects are experienced or all are contraindicated (a and b):
   a. A taxane-based regimen (e.g., docetaxel);*
      *Prior authorization may be required for taxanes
   b. Abiraterone (Zytiga®), unless member has previously failed Yonsa® (abiraterone) or Xtandi® (enzalutamide);*
      *Prior authorization may be required for Zytiga, Yonsa, and Xtandi
8. Member has not previously received a PARP inhibitor (e.g., Lynparza, Talzenna, Zejula) (see Appendix D);
9. Request meets one of the following (a or b):*
   a. Dose does not exceed 1,200 mg per day (4 capsules per day);
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Medicaid/HIM – 6 months
Commercial – Length of Benefit
C. Other diagnoses/indications
   1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
   A. All Indications in Section I (must meet all):
      1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Rubraca for a covered indication and has received this medication for at least 30 days;
      2. Member is responding positively to therapy;
      3. For Rubraca request, medical justification supports inability to use rucaparib, if available, (e.g., contraindications to excipients);
      4. If request is for a dose increase, request meets one of the following (a or b):*
         a. New dose does not exceed 1,200 mg (4 tablets) per day;
         b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
      *Prescribed regimen must be FDA-approved or recommended by NCCN

   Approval duration:
   Medicaid/HIM – 12 months
   Commercial – Length of Benefit

   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
      
      Approval duration: Duration of request or 6 months (whichever is less); or

      2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   ADT: androgen deprivation therapy
   BRCA: breast cancer susceptibility gene
   CRPC: castration resistant prostate cancer
   FDA: Food and Drug Administration
   GnRH: gonadotropin-releasing hormone
   LHRH: luteinizing hormone-releasing hormone
   NCCN: National Comprehensive Cancer Network
   PARP: poly (ADP-ribose) polymerase
Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/ Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ovarian Cancer: examples of chemotherapy agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alimta® (pemetrexed)</td>
<td>Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>Alkeran® (melphalan)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avastin® (bevacizumab)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>carboplatin (Paraplatin®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cisplatin (Platinol-AQ®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cyclophosphamide (Cytoxan®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>docetaxel (Taxotere®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>doxorubicin (Doxil®, Adriamycin®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>etoposide (Vepesid®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>gemcitabine (Gemzar®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ifosfamide (Ifex®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>irinotecan (Camptosar®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>oxaliplatin (Eloxatin®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>topotecan (Hycamtin®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hexalen® (altretamine)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>paclitaxel</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prostate Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>docetaxel</td>
<td>75 mg/m² IV for 6 cycles</td>
<td>Varies</td>
</tr>
<tr>
<td>abiraterone (Zytiga®, Yonsa®)</td>
<td>Zytiga: 1,000 mg PO BID in combination with prednisone</td>
<td>1,000 mg QD; 1,000 mg BID if taking a strong CYP3A4 inducer</td>
</tr>
<tr>
<td></td>
<td>Yonsa: 500 mg PO QD in combination with methylprednisolone</td>
<td>Yonsa: 500 mg QD; 500 mg BID if taking a strong CYP3A4 inducer</td>
</tr>
<tr>
<td>enzalutamide (Xtandi®)</td>
<td>160 mg PO QD</td>
<td>160 mg/day; 240 mg/day if taking a strong CYP3A4 inducer</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings
None reported

Appendix D: General Information
- CRPC is prostate cancer that progresses clinically, radiographically, or biochemically despite castrate levels of serum testosterone (< 50 ng/dL). Per the NCCN, androgen
deprivation therapy (ADT) should be continued in the setting of CRPC while additional therapies are applied.

- Examples of ADT include:
  - Bilateral orchietomy (surgical castration)
  - Luteinizing hormone-releasing hormone (LHRH; also known as GnRH) given with or without an anti-androgen:
    - LHRH agonists: Zoladex® (goserelin), Vantas® (histrelin), leuprolide (Lupron Depot®, Eligard®), and Trelstar® (triptorelin)
    - Anti-androgens: bicalutamide (Casodex®), flutamide, nilutamide (Nilandron®), Xtandi® (enzalutamide), Erleada® (apalutamide)
  - LHRH antagonist: Firmagon® (degarelix)

- There are insufficient data regarding the use of consecutive PARP inhibitors. Most PARP inhibitor pivotal trials excluded prior PARP inhibitor use. The NCCN does not make any explicit recommendations in this regard (other than for ovarian cancer, where it states data is limited), and there are no randomized controlled trials evaluating such use.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovarian cancer</td>
<td>600 mg PO BID.</td>
<td>1,200 mg/day</td>
</tr>
<tr>
<td>Metastatic CRPC</td>
<td>600 mg PO BID. Patients receiving Rubraca should also receive a GnRH analog concurrently or should have had bilateral orchietomy</td>
<td>1,200 mg/day</td>
</tr>
</tbody>
</table>

VI. Product Availability

Tablets: 200 mg, 250 mg, 300 mg

VII. References


Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New policy created. Clarified two prior chemo regimens; added examples of specific ovarian cancer types. Revised general formatting and updated therapeutic alternatives</td>
<td>1.5.17</td>
<td>02.17</td>
</tr>
<tr>
<td>Updated BRCA testing to allow for somatic mutations</td>
<td>3.10.17</td>
<td>05.17</td>
</tr>
<tr>
<td>Reviews, Revisions, and Approvals</td>
<td>Date</td>
<td>P&amp;T Approval Date</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Minor changes to verbiage and grammar. References updated.</td>
<td>06.17</td>
<td>11.17</td>
</tr>
<tr>
<td>1Q18 annual review: No significant clinical changes; added Age ≥18 years per PI; Updated Appendix B with additional acceptable prior treatment regimens based on NCCN Ovarian Cancer guidelines; references reviewed and updated.</td>
<td>11.13.17</td>
<td>02.18</td>
</tr>
<tr>
<td>Criteria added for new FDA indication: maintenance treatment of ovarian cancer which is in complete/partial response to platinum-based chemotherapy; references reviewed and updated.</td>
<td>05.29.18</td>
<td>08.18</td>
</tr>
<tr>
<td>1Q 2019 annual review: no significant changes; references reviewed and updated.</td>
<td>11.20.18</td>
<td>02.19</td>
</tr>
<tr>
<td>1Q 2020 annual review: no significant changes; added HIM line of business; added quantity limit of 4 tablets for max dosing; references reviewed and updated.</td>
<td>10.29.19</td>
<td>02.20</td>
</tr>
<tr>
<td>Criteria added for new FDA indication: metastatic CRPC; for both indications, added requirement against prior use of a PARP inhibitor; added Appendix D; references reviewed and updated.</td>
<td>06.15.20</td>
<td>08.20</td>
</tr>
<tr>
<td>RT4: mCRPC label update to require FDA-approved diagnostic test - no change to mCRPC indication. 1Q 2021 annual review: oral oncology generic redirection language added; for ovarian cancer, single-agent therapy clarification added; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated.</td>
<td>11.14.20</td>
<td>02.21</td>
</tr>
</tbody>
</table>

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.
This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members,** when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.